HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (5- hydroxy- 3- methyl- 1- phenyl- 1H- pyrazol- 4- yl)- 6- methyl- 1,3- dihydrofuro(3,4- c)pyridine- 7- ol

inhibits advanced glycation, oxidative stress, and ER stress; a neuroprotective agent

Also Known As:

TM 2002; TM-2002; TM2002

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1,3-dihydrofuro(3,4-c)pyridine-7-ol: 4
  - Furans: 85
    - 1-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1,3-dihydrofuro(3,4-c)pyridine-7-ol: 4

Experts

1.	Miyata, Toshio: 3 articles (08/2009 - 12/2007)
2.	Izuhara, Yuko: 2 articles (02/2008 - 12/2007)
3.	Takizawa, Shunya: 2 articles (02/2008 - 12/2007)
4.	van Ypersele de Strihou, Charles: 2 articles (02/2008 - 12/2007)
5.	Guo, Qi: 1 article (08/2009)
6.	Hosoya, Takuma: 1 article (08/2009)
7.	Hu, Chunyan: 1 article (08/2009)
8.	Ito, Sadayoshi: 1 article (08/2009)
9.	Jiang, Yue: 1 article (08/2009)
10.	Kawamata, Akihiro: 1 article (08/2009)

Related Diseases

1.	Ischemia 12/05/2007 - "In permanent focal ischemia, TM2002 (2.79, 5.58, and 11.16 mg/kg twice a day) dose-dependently reduced infarct volume (242.1+/-32.3, 201.3+/-15.1, and 171.3+/-15.2 mm3, respectively), and improved neurological deficits. " 12/05/2007 - "In transient focal ischemia, TM2002 significantly decreased infarct volume compared with vehicle (79.5+/-18.7 vs. 183.3+/-22.9 mm3, p<0.01). "
2.	Insulin Resistance 08/01/2009 - "Four-week treatment with NAC or TM2002 completely improved methylglyoxal-induced insulin resistance. "
3.	Infarction (Infarctions) 12/05/2007 - "Reduction of infarct volume is demonstrable, provided that TM2002 was administered within 1.5 h after the occlusion. " 12/05/2007 - "In permanent focal ischemia, TM2002 (2.79, 5.58, and 11.16 mg/kg twice a day) dose-dependently reduced infarct volume (242.1+/-32.3, 201.3+/-15.1, and 171.3+/-15.2 mm3, respectively), and improved neurological deficits. " 12/05/2007 - "In transient focal ischemia, TM2002 significantly decreased infarct volume compared with vehicle (79.5+/-18.7 vs. 183.3+/-22.9 mm3, p<0.01). "
4.	Carotid Artery Injuries 02/01/2008 - "In four different rat models of renal injury (anti-Thy1 and ischaemia-reperfusion) and cardiovascular injury (carotid artery balloon injury and angiotensin II-induced cardiac fibrosis), TM2002 improves renal and cardiovascular lesions without modification of blood pressure. "
5.	Fibrosis (Cirrhosis) 02/01/2008 - "In four different rat models of renal injury (anti-Thy1 and ischaemia-reperfusion) and cardiovascular injury (carotid artery balloon injury and angiotensin II-induced cardiac fibrosis), TM2002 improves renal and cardiovascular lesions without modification of blood pressure. "

Related Drugs and Biologics

1.	Pyruvaldehyde (Methylglyoxal)
2.	Polyphenols
3.	Tunicamycin
4.	Tea
5.	Angiotensin II
6.	epigallocatechin gallate (epigallocatechin-3-gallate)